Ignite Creation Date:
2025-12-24 @ 9:44 PM
Ignite Modification Date:
2025-12-31 @ 8:46 PM
Study NCT ID:
NCT00000232
Status:
COMPLETED
Last Update Posted:
2016-05-06
First Post:
1999-09-20
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Alternate Day Buprenorphine Administration, Phase IX - 14
Sponsor:
University of Vermont
Organization:
Study Overview
Official Title:
Alternate Day Buprenorphine Administration, Phase IX
Status:
COMPLETED
Status Verified Date:
1994-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determine if four times a subjects' daily maintenance dose will hold for 120 hours without changes in agonist and antagonist effects.
Detailed Description:
None
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?:
Secondary ID Infos
| Secondary ID | Type | Domain | Link | View |
|---|---|---|---|---|
| R01DA006969 | NIH | None | https://reporter.nih.gov/quic… | View |
| R01-06969-14 | None | None | View |